Pharma stock jumps 5% after reporting 64.5% YoY increase in net profitsPharma stock jumps 5% after reporting 64.5% YoY increase in net profits

Introduction:

Pharma stock saw a strong performance in Q3FY25, with a 64.5% YoY growth in net profit to ₹589 crore. Revenue rose 25.01% YoY to ₹2,319 crore. The stock surged nearly 5%, reflecting market confidence in the company’s robust results.

Share Price movement of Divi’s Laboratories:

On February 3, 2025, Divi’s Laboratories Ltd opened at ₹5,619.00, the stock reached a high of ₹5,955.10 up 5.9% from its previous close of ₹5,618.55 and a low of ₹5,471.00. It closed at ₹5,949.90, with a market cap of ₹1,57,951.15 crore.

Divi’s Laboratories Q3 Results: 

Divi’s Laboratories reported a 64.5% YoY increase in net profit for Q3FY25, reaching ₹589 crore, up from ₹358 crore in Q3FY24. This robust growth reflects the company’s strong performance in the fiscal third quarter, leading to positive market reactions.

The company’s revenue for Q3FY25 stood at ₹2,319 crore, marking a 25.01% increase from ₹1,855 crore in Q3FY24. Despite the year-on-year growth, the revenue saw a slight dip of nearly 1% compared to the previous quarter, indicating a minor sequential slowdown.

Profit before tax (PBT) for the quarter amounted to ₹726 crore, significantly higher than ₹489 crore in Q3FY24, showing an impressive growth trajectory. Divi’s Laboratories’ stock surged nearly 4% following the strong results, with shares trading at ₹5,835.65 at 13:22 on BSE.

Also Read: Jewellery stock hits 5% upper circuit after its net profit increases by 309% in Q3

Recent news About Divi’s Laboratories :

On December 4, 2024, Divi’s Laboratories Ltd reported receiving a ₹6 lakh penalty from the Directorate of Enforcement, Hyderabad, for procedural delays in submitting Annual Performance Reports for investments in overseas subsidiaries. The penalty has no impact on the company’s operations.

Stock performance of Divi’s Laboratories for Period of 1 week, 6 months and 1 year:

Divi’s Laboratories stock has gained 3.97% over the past week, reflecting short-term growth. Over the last 6 months, it saw a 17.2% increase, demonstrating steady growth. Over the past year, the stock performed exceptionally well, with a 56.7% return, indicating strong long-term performance.

Also Read:  Stock jumps 3% after it receives order from Ministry of Railways

Shareholding pattern of Divi’s Laboratories:

All values in %	Dec-24	Sep-24	Jun-24
Promoters	51.89	51.89	51.9
FII	17.98	17.25	16.16
DII	20.53	21.07	21.76
Retail & others	9.58	9.79	10.17

About Divi’s Laboratories:

Divi’s Laboratories is a leading global pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Known for its high-quality production, the company serves clients across the pharmaceutical, biotechnology, and nutraceutical industries worldwide.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.